top of page
Pipeline
Current Applications
Diabetic Wound Healing
• hOMSC200 for Diabetic Foot Ulcers.
• Diabetic Foot Ulcer (DFU) – Successful completion of Phase I/IIa clinical trial Q1/25.
Central & Autonomic Nervous System
• hOMSC300 for Multiple System Atrophy patients.
• Multiple System Atrophy (MSA) – Phase I Clinical Studies in progress.
Patent Protected IP
Cytora is the only company that holds an exclusive license for the production & commercialization of hOMSC.
4 Patent families
7 Granted patents
9 Patent applications
hOMSC themselves, their production and their use for any purpose are protected by granted patents
(US, Europe, China, India).
bottom of page